Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Research & Development (2020 - 2026)

Design Therapeutics' Research & Development history spans 2 years, with the latest figure at $7.3 million for Q4 2021.

  • On a quarterly basis, Research & Development rose 170.94% to $7.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $24.8 million, a 308.88% increase, with the full-year FY2025 number at $100000.0, down 99.77% from a year prior.
  • Research & Development hit $7.3 million in Q4 2021 for Design Therapeutics, down from $8.5 million in the prior quarter.
  • Over the last five years, Research & Development for DSGN hit a ceiling of $8.5 million in Q3 2021 and a floor of $377000.0 in Q1 2020.